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ardiac Resynchronization Devices
he Food and Drug Administration’s Regulatory Considerations
egan Moynahan, MS, Owen P. Faris, PHD, Brian M. Lewis, MD
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Cardiac resynchronization therapy (CRT) devices have been studied clinically since 1998, and
have been on the U.S. market since the Food and Drug Administration (FDA) approval of
the first product in 2001. Since that time, the FDA has approved many different models from
three different manufacturers, representing the first and second generations of these products.
All of these products have undergone the FDA pre-market approval process, which examines
the safety and effectiveness of the devices for their intended use. Over the last several years,
the FDA has adapted recommendations for CRT clinical trials based on an evolving
understanding of what these devices can achieve. This paper will outline the dynamic nature
of the FDA’s approval process for CRT devices and briefly review the clinical trial designs for
the first generation devices. (J Am Coll Cardiol 2005;46:2325–8) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.068College of Cardiology Foundation
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she U.S. Food and Drug Administration’s (FDA) regula-
ory authority over medical devices extends to both their
nvestigational use and market approval. The FDA’s regu-
atory system is a risk-based system, with different require-
ents depending on the degree of risk posed by devices
Table 1). Pacemakers, implantable defibrillators, and car-
iac resynchronization therapy (CRT) devices, therefore,
re classified into the highest risk category, class III. These
evices must meet stringent manufacturing controls and
igorous bench and animal testing and typically require
linical trials to fully evaluate device performance.
Regulations governing medical devices review and ap-
roval were modeled after the regulations established for
rug approvals. Similar to drugs, devices must have a safety
nd effectiveness evaluation which supports an acceptable
isk-benefit profile to gain approval. Manufacturing controls
re considered as part of the review process, because it is
hrough manufacturing controls that product consistency
an be assured. Just as with drugs, individual devices are
enerally evaluated on a case-by-case basis. The FDA does
ot assume that devices are interchangeable across manu-
acturers; safety, effectiveness, and target population find-
ngs from a clinical trial evaluating one manufacturer’s
evice may have limited applicability to another manufac-
urer’s device.
Medical devices differ from drugs in that they may fail
uickly, unpredictably, and late in their use. Physician
echnique, particularly for implantable devices, may strongly
mpact device performance and patient outcomes. Addi-
ional risks may occur through biologic incompatibility and
nteractions with other medical devices or equipment such
s magnetic resonance imaging or other electromagnetic
From the Center for Devices and Radiological Health, U.S. Food and Drugi
dministration, Rockville, Maryland.
Manuscript received April 13, 2005, accepted May 4, 2005.ources. Medical devices may even have a shorter market life
han drugs. They are continually being modified to meet
ser needs, to improve manufacturing yields, or to correct
eficiencies in design. The FDA’s processes evaluate the
ncremental impact of these modifications on safety and
ffectiveness.
The FDA’s understanding of CRT informs clinical rec-
mmendations for demonstrating safety and effectiveness.
his understanding evolves by evaluating marketing appli-
ations, reviewing publicly available information, consulting
ith our advisory panel, and observing device performance
nd patient outcomes during the post-market period. Since
he approval of the Medtronic (Minneapolis, Minnesota)
nSync Biventricular Pacing System in 2001, the FDA has
pproved over two dozen CRT models from three different
anufacturers. The first devices were evaluated in random-
zed blinded clinical trials comparing CRT-on to CRT-off
Table 2). The knowledge gained from these trials and
ubsequent field experience has allowed certain modifica-
ions to the approved technology to be fully evaluated based
pon limited clinical data or bench testing alone.
RT EFFECTIVENESS
egarding effectiveness, FDA approval of medical devices
equires that “there is reasonable assurance that a device is
ffective when it can be determined, based upon valid
cientific evidence, that in a significant portion of the target
opulation, the use of the device for its intended uses and
onditions of use, when accompanied by adequate directions
or use and warnings against unsafe use, will provide
linically significant results” (1). Thus, the data must sup-
ort a clinically meaningful outcome in at least a patient
ubset.
In the first clinical trials, the FDA asked manufacturers to
nvestigate whether CRT provided reasonable effectiveness
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CRT Devices: Regulatory Considerations December 20, 2005:2325–8s an adjunct to optimal pharmacologic therapy for heart
ailure. Based on the FDA’s understanding of the potential
emodynamic effect from CRT, early studies assessed exer-
ise tolerance and quality of life in symptomatic patients.
The FDA convened its Circulatory System Devices Panel
o interpret outcomes of trials for the first three applications
or CRT: Medtronic’s InSync (2), Guidant’s (St. Paul, Min-
esota) Contak CD (3), and Medtronic’s InSync ICD (4).
xperts in both heart failure management and electrophysi-
logy focused on whether: 1) patients received standard
ptimal medical therapy, particularly beta blockers; 2) re-
ponder subgroups could be identified; and 3) the benefit was
linically meaningful across the population studied.
Panel concerns about bias from potential unblinding led
o later recommendations for more objective endpoints such
s peak oxygen consumption. Nevertheless CRT trials still
nclude subjective measures such as quality of life, 6-min
alk, and New York Heart Association (NYHA) function
lass because they are felt to be clinically meaningful.
RT SAFETY
o meet the FDA’s requirement for reasonable safety in a
pecific target population, manufacturers must provide
valid scientific evidence that the probable benefits to health
rom use of the device for its intended uses and conditions
f use, when accompanied by adequate directions and warn-
ngs against unsafe use, outweigh the probable risks” (5).
In early clinical trials for CRT, the FDA evaluated
onventional device- and procedure-related adverse events
nd data characterizing worsening heart failure such as
umber of heart failure hospitalizations, use of inotropes,
nd worsening symptoms.
Coronary sinus leads have presented unique acute and
hronic safety concerns owing to a variety of lead shapes and
xation mechanisms. Trials have assessed lead safety through
otal procedure time, lead implant time, fluoroscopy time,
ead implant success rate, and adverse events specifically
Abbreviations and Acronyms
CRT  cardiac resynchronization therapy
EF  ejection fraction
FDA  Food and Drug Administration
ICD  implantable cardioverter-defibrillator
LV  left ventricular
NYHA  New York Heart Association
able 1. Food and Drug Administration Classification of
edical Devices
Class Examples
lass I Manual stethoscope, cardiovascular surgical instruments
lass II Vascular grafts (excluding coronary), biliary stents, PTA
catheters
lass III Pacemakers, implantable defibrillators, cardiac
resynchronization devices, endovascular grafts, vasculartstents, coronary artery bypass grafts, heart valvesssociated with the lead (e.g., coronary sinus dissection,
erforation, lead revisions, diaphragmatic stimulation, and
islodgements). The FDA recognized that physician expe-
ience and lead-related instruction strongly impacted safety
nd therefore mandated training as a condition of approval.
Many CRT devices were originally developed on an
mplantable cardioverter-defibrillator (ICD) platform. In
he U.S., most CRT devices now have this configuration,
ecause the majority of CRT recipients are also candidates
or an ICD. Concern that CRT could interfere with
efibrillation was addressed in the clinical trials by second-
ry endpoints that confirmed ICD functionality.
Device reliability is a primary component of safety often
etter evaluated outside clinical trials. Bench tests are used
o study rare events such as catastrophic failure, demonstrate
ppropriate levels of mechanical durability, biocompatibil-
ty, immunity from electrical noise, and hermeticity, and
heck standard measures of device safety. Bench testing of
revious pacemakers and defibrillators provided the FDA
ith a valuable foundation in this regard.
NDICATIONS
he indications statement describes the population in whom a
evice is demonstrated to be safe and effective. Based on
arly clinical trials, currently marketed CRT devices are
ndicated for patients with low ejection fraction (EF),
rolonged QRS duration and moderate to severe heart
ailure (NYHA functional class III/IV) despite stable, op-
imal medical therapy. Specific QRS durations and EFs
ere derived directly from enrollment criteria. However, the
DA’s panel determined that sufficient benefit was not
emonstrated for class II patients, so the NYHA functional
lass indication was subsequently limited. Importantly, the
opulation the FDA indicates for a device may differ from
hat eligible for Center for Medicare and Medicaid Services
eimbursement.
OTAL PRODUCT LIFE CYCLE
he FDA’s regulatory authority extends beyond the initial
arket approval of a device through post-market studies,
upplemental applications for device modifications, and
eporting of device problems.
ost-market studies. Post-market studies can be required
y the FDA as a condition of approval. These studies
rovide information about long-term patient outcomes and
evice performance, which is not considered as necessary to
ake a pre-market approval decision but is nevertheless
mportant to characterize. All original CRT device approv-
ls have required a post-market study. The FDA’s primary
oal was to characterize outcomes beyond the six months of
re-market evaluation. These post-market studies were also
esigned to capture long-term electrical performance of the
eft ventricular (LV) leads. The FDA receives six-month
pdates regarding these studies. This information, in addi-
ion to other recent trial results (6,7), continues to shape the
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December 20, 2005:2325–8 CRT Devices: Regulatory ConsiderationsDA’s thinking and expectations for CRT device perfor-
ance.
evice modification. Manufacturers propose device mod-
fications when they seek to improve safety or effectiveness,
xpand utility, optimize manufacturing yields, or address
ost-market safety concerns. Following the least-burdensome
pproach, the FDA considers the incremental risks and ben-
fits of device changes and identifies the types of evidence
eeded to characterize safety and effectiveness. When the
otential clinical impact of changes can be well character-
zed through bench or animal testing, a clinical trial may not
e required. When important clinical outcomes such as
ymptoms or mortality must be evaluated, or when the
anufacturer wishes to expand the intended patient popu-
ation for the device, a clinical trial is needed. New patient
opulations are reflected in the approved labeling for the
evice.
ecalls. Device recalls provide a way to link safety concerns
rom a variety of sources (including voluntary medical device
eports) to coordinated action and recommendations by
anufacturers and the FDA. Recent implantable pace-
aker and defibrillator recalls have pertained to electrical
ircuitry abnormalities, battery and capacitor malfunctions,
nd anomalous behavior of firmware (8). If the correction
nvolves a change to either the manufacturing process or the
esign of the device itself, a supplemental application to the
DA is required.
UTURE DIRECTIONS FOR CRT DEVICES
oth CRT devices and their indicated populations evolve as
he market for CRT expands. New technologies may allow
hysicians to better tailor therapy to the needs of particular
atients or offer diagnostic enhancements that aid overall
are. As new patient populations are investigated, the medical
able 2. Primary Effectiveness End Points
Study Design
InSync
(Medtronic)
InSync ICD
(Medtronic)
ear study began 1998 1999
ear device approved 2001 2002
ype of device CRT-P CRT-D
omparison CRT on vs. off CRT on vs. off
ollow-up 1, 3, 6 months 1, 3, 6 months
linding Double Double
rimary effectiveness
end point
NYHA functional class,
6-min walk, QOL*
NYHA functional cl
6-min walk, QOL
dditional effectiveness
end points
Mortality, peak VO2,
QRS, hospitalization,
echo measures,
neurohormones
Mortality, peak VO2,
QRS, hospitalizati
echo measures,
neurohormones
ample size (total
randomized)
532 555
The trial design defined success as occurring if any one of the three end points was
f all three were significant at alpha  0.05. †The trial design defined success as occ
esulted in p  0.10; or 2) peak VO2 improved 0.5 ml/kg/min (p  0.10) and 6-M
CRT  cardiac resyncronization therapy; HF  heart failure; NYHA  New Yo
brillation; VO2  oxygen consumption.ommunity may better understand who is most likely to senefit from CRT. Importantly, these studies may require
ew clinical endpoints better suited to their populations.
ew CRT technologies. Since the first approvals, the
edical community and industry have sought to optimize
RT by varying parameters such as electrode placement and
timulus timing. These pursuits have led to the development
f devices that more flexibly deliver CRT. For example,
ome devices offer a variable delay between right and LV
ulses. There has been considerable demand by clinicians
or new lead designs which allow greater control over where
timulation is delivered. Critical to the implementation of
hese technologies, however, is an understanding of how to
ptimize cardiac function. Many questions remain about the
elative importance of intraventricular and interventricular
lectrical and mechanical timing and their role in cardiac
unction and heart failure progression.
Although CRT device diagnostics are predominantly
imited to electrophysiologic concerns such as battery life,
acing capture, or integrity of lead conduction, future
evices will likely incorporate novel diagnostic measures
hat may help characterize the heart failure status of
atients. While such features offer promise, their implemen-
ation presents new concerns, such as how such data would
e presented to the physician and how those data should be
nterpreted, especially if traditional diagnostics are absent or
ontradict the device. Further, adequate specificity and sensi-
ivity are needed to avoid unnecessary hospitalizations or
nterventions on the one extreme and misinformed compla-
ency on the other.
ew CRT populations. Although indications are not
dentical across manufacturers, most approved CRT devices
re currently indicated for patients with moderate to severe
eart failure (NYHA functional class III/IV) who have LV
ysfunction and prolonged QRS duration and remain
Contak CD
(Guidant)
Contak TR
(Guidant)
Epic HF
(St. Jude)
1998 2000 2002
2002 2004 2004
CRT-D CRT-P CRT-D
CRT on vs. off CRT on vs. off CRT on vs. off
0, 3, 6 months 0, 3, 6 months 0, 1, 3, 6 months
Double Unblinded Double
Composite index (mortality,
HF hospitalizations,
therapy for VT/VF)
Peak VO2, 6-min
walk†
Peak VO2
Peak VO2, QOL, 6-min walk,
NYHA functional class,
echo measures,
norepinephrine, heart rate
QOL and
NYHA
functional class
6-min walk, QOL,
NYHA
functional class,
echo measures
490 448 178
ically significant at alpha  0.0167, if any two were significant at alpha  0.025, or
if: 1) peak VO2 improved 0.7 ml/kg/min (p  0.05) and 6-MWD improvement
improvement resulted in p  0.05.
rt Association; QOL  quality of life; VT/VF  ventricular tachycardia/ventricularass,
*
on,
statist
urring
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CRT Devices: Regulatory Considerations December 20, 2005:2325–8py. It is unknown, however, whether CRT may benefit
ther heart failure populations and, if so, how such benefit
hould be assessed. For example, it is unknown whether
RT may help to slow or reverse the progression of heart
ailure in asymptomatic patients (NYHA functional class
/II) who have depressed LV function and prolonged QRS,
atients with diastolic dysfunction and preserved EF, or
atients who have contractile dyssynchrony but normal
lectrical timing. The risks and benefits of CRT will have to
e demonstrated in these patients in order for a manufac-
urer to expand the indicated patient population for its
evice.
ew clinical end points. The original pivotal CRT trials
ocused largely on exercise response and functional status.
ore recently, two large trials explored mortality and
orbidity benefits (6,7). As trials target asymptomatic
opulations, however, alternative assessments of patient
utcome may provide additional information. Some of the
ost promising parameters, such as those based on CRT-
nduced changes in systolic and diastolic dimension, may
ne day shed light into reverse remodeling. Generally
ssessed by echocardiography, these noninvasive measures
ay offer early and meaningful surrogates of heart failure
rogression and potential reversal if clinically meaningful
tandards for interpretation are developed.
ONCLUSIONS
evice-based therapies for heart failure are reviewed and
pproved by the FDA based on an evaluation of each
evice’s safety and effectiveness. The FDA’s approval of
RT devices hinges on a belief that these products are stilldjunctive therapy for patients on an optimal medical regimen.
s clinical trials continue to explore responder groups and
urther our understanding of how patients benefit from
hese devices, the FDA’s clinical trial recommendations will
ikewise evolve. Using this dynamic review process, the
DA will continue to meets its public health mission of
nsuring safe and effective device therapies for heart failure
atients.
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